ArticleCancer chemotherapy and pharmacology2024

Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.

Anita Moein et al.PubMed ↗Publisher ↗

No numbers read from the abstract.